Head-To-Head Survey: Merck & (MRK) & The Competitors


Merck & (NYSE: MRK) is certainly one of 116 public firms within the “Prescribed drugs” trade, however how does it examine to its rivals? We are going to examine Merck & to comparable companies primarily based on the energy of its badyst suggestions, profitability, threat, institutional possession, earnings, dividends and valuation.

Threat and Volatility

Merck & has a beta of zero.Eight, indicating that its inventory value is 20% much less unstable than the S&P 500. Comparatively, Merck &’s rivals have a beta of zero.89, indicating that their common inventory value is 11% much less unstable than the S&P 500.


This desk compares Merck & and its rivals’ internet margins, return on fairness and return on belongings.

Web Margins Return on Fairness Return on Belongings
Merck & 11.60% 26.82% 11.31%
Merck & Rivals -2,859.57% -67.49% -Eight.86%

Insider and Institutional Possession

72.9% of Merck & shares are held by institutional buyers. Comparatively, 44.three% of shares of all “Prescribed drugs” firms are held by institutional buyers. zero.three% of Merck & shares are held by firm insiders. Comparatively, 12.zero% of shares of all “Prescribed drugs” firms are held by firm insiders. Robust institutional possession is a sign that hedge funds, mbadive cash managers and endowments imagine a inventory will outperform the market over the long run.

Analyst Suggestions

This can be a breakdown of present rankings and recommmendations for Merck & and its rivals, as reported by MarketBeat.

Promote Rankings Maintain Rankings Purchase Rankings Robust Purchase Rankings Score Rating
Merck & 1 9 7 zero 2.35
Merck & Rivals 839 3767 6794 185 2.55

Merck & presently has a consensus goal value of $67.38, suggesting a possible upside of 23.17%. As a bunch, “Prescribed drugs” firms have a possible upside of 24.85%. Given Merck &’s rivals stronger consensus score and increased attainable upside, badysts plainly imagine Merck & has much less favorable progress elements than its rivals.

Earnings & Valuation

This desk compares Merck & and its rivals gross income, earnings per share and valuation.

Gross Income EBITDA Value/Earnings Ratio
Merck & $40.02 billion $15.45 billion 32.76
Merck & Rivals $Eight.20 billion $2.68 billion -1.59

Merck & has increased income and earnings than its rivals. Merck & is buying and selling at a better price-to-earnings ratio than its rivals, indicating that it’s presently dearer than different firms in its trade.


Merck & pays an annual dividend of $1.88 per share and has a dividend yield of three.four%. Merck & pays out 112.6% of its earnings within the type of a dividend, suggesting it could not have ample earnings to cowl its dividend fee sooner or later. As a bunch, “Prescribed drugs” firms pay a dividend yield of two.5% and pay out 66.zero% of their earnings within the type of a dividend. Merck & has raised its dividend for five consecutive years.


Merck & beats its rivals on Eight of the 15 elements in contrast.

Merck & Firm Profile

Merck & logoMerck & Co., Inc. is a world healthcare firm. The Firm affords well being options via its prescription medicines, vaccines, biologic therapies and animal well being merchandise. It operates via 4 segments: Pharmaceutical, Animal Well being, Healthcare Providers and Alliances. The Firm’s Pharmaceutical phase contains human well being pharmaceutical and vaccine merchandise marketed both straight by the Firm or via joint ventures. Human well being pharmaceutical merchandise encompbad therapeutic and preventive brokers, usually bought by prescription, for the therapy of human problems. The Firm sells its human well being pharmaceutical merchandise primarily to drug wholesalers and retailers, hospitals, authorities companies and managed healthcare suppliers, equivalent to well being upkeep organizations, pharmacy profit managers and different establishments. Vaccine merchandise encompbad preventive pediatric, adolescent and grownup vaccines, primarily administered at doctor places of work.

Obtain Information & Rankings for Merck & Firm Inc. Each day – Enter your e mail deal with beneath to obtain a concise each day abstract of the newest information and badysts’ rankings for Merck & Firm Inc. and badociated firms with MarketBeat.com’s FREE each day e mail e-newsletter.

Supply hyperlink

Leave a Reply

Your email address will not be published.